TORONTO, Nov. 14,
2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focused on central
nervous system and cardiovascular markets, announces that
Gilbert Godin, CEO, and Tim Hendrickson, CFO, will take part in a
fireside chat with Stifel Healthcare analyst, Justin Keywood, at the 2022 Stifel Healthcare
Conference on Wednesday November 16,
2022 at 8:35 a.m. Eastern
Time. The conference is being held at the Lotte New York
Palace Hotel in New York City.
The Company's fireside chat will be webcast at:
https://wsw.com/webcast/stifel74/hls.to/2368752
HLS will also host one-on-one meetings with investors at the
conference. To request a one-on-one meeting, please contact your
Stifel representative.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.